Introduction to Immunocore
Immunocore is a visionary biotechnology company headquartered in Abingdon, Oxfordshire, United Kingdom, with additional offices in Rockville, Maryland, USA, and Frankfurt, Germany. As a global leader in T-cell receptor (TCR) technology, Immunocore specializes in developing novel immunotherapies that harness the power of the immune system to treat cancer, infectious diseases, and autoimmune disorders. The company's proprietary ImmTAC (Immune mobilizing monoclonal T Cell receptors Against Cancer) platform represents a paradigm shift in targeted immunotherapy, enabling precise recognition of intracellular antigens presented by HLA molecules. With a market capitalization exceeding $2 billion and a robust pipeline including tebentafusp (Kimmtrak), the first TCR-based therapy approved by the FDA and EMA for metastatic uveal melanoma, Immunocore has established itself as a trailblazer in the oncology landscape. The company's commitment to scientific excellence, patient-centric innovation, and strategic partnerships with leading academic institutions and pharmaceutical giants like GlaxoSmithKline underscores its reputation as a top-tier healthcare organization. Immunocore's research and development efforts are supported by a talented workforce of over 500 employees, including world-class immunologists, clinicians, and biotechnologists, dedicated to transforming the lives of patients with high unmet medical needs.
Company History and Business Evolution
Immunocore was founded in 2008 as a spin-out from the UK Medical Research Council's Laboratory of Molecular Biology in Cambridge, drawing on pioneering research by Sir Greg Winter and colleagues. The company initially focused on developing soluble T-cell receptors as therapeutic agents, a concept that was both scientifically ambitious and commercially unproven. Early milestones included securing venture capital funding from institutions like Abingworth, IP Group, and Pfizer Venture Investments, enabling the advancement of its ImmTAC platform. In 2015, Immunocore announced a landmark collaboration with GlaxoSmithKline to develop ImmTAC molecules against multiple cancer targets, validating the platform's potential. The company's most significant breakthrough came in 2022 with FDA approval of tebentafusp for metastatic uveal melanoma, a rare and aggressive cancer with no previously approved therapies. This approval marked the first-ever regulatory nod for a TCR-based therapy and cemented Immunocore's position as a pioneer in the field. Subsequent expansion included a successful IPO on the NASDAQ in 2021 (IMCR), raising over $300 million to fuel pipeline growth. The company has also broadened its research into bispecific proteins, cytokine-based therapies, and combination regimens, continuously evolving its scientific toolkit. Recent years have seen Immunocore enter Phase 2 and Phase 3 trials for multiple indications, including hepatitis B and solid tumors, while expanding its manufacturing capabilities in the UK. The company's trajectory reflects a steady ascent from a small spin-out to a commercially-stage biopharmaceutical powerhouse, driven by relentless innovation and a clear vision for transforming immunotherapy.
Immunocore at a Glance
- Headquarters: Abingdon, Oxfordshire, United Kingdom
- Founded: 2008
- CEO: Dr. Bahija Jallal (as of 2024)
- Employee Count: Approximately 550
- Revenue (2023): £146 million (primarily from tebentafusp sales)
- Stock Symbol: IMCR (NASDAQ)
- Industry: Biotechnology (immuno-oncology, TCR therapeutics)
- Key Product: Kimmtrak (tebentafusp) – first TCR therapy approved
- Pipeline: 10+ programs in oncology, infectious diseases, and autoimmune
- Key Partners: GlaxoSmithKline, Genentech, University of Oxford
- Technology Platform: ImmTAC (Immune mobilizing monoclonal T Cell receptors Against Cancer)
- Regulatory Milestones: FDA approval (2022), EMA approval (2022)
- Manufacturing: In-house GMP facility in Abingdon
- Global Presence: UK, USA (Maryland), Germany (Frankfurt)
- Funding History: Over $600 million raised from VCs and IPO
- Clinical Trials: Active Phase 2/3 in melanoma, HBV, NSCLC
- Recognition: Included in FT 1000 Europe, named Best Biotech Employer by Science Magazine
- Intellectual Property: 200+ patents granted worldwide
- Corporate Culture: Emphasis on innovation, diversity, and patient focus
- Community Engagement: Partnerships with patient advocacy groups, CSR initiatives in STEM education
Mission, Vision, and Core Corporate Values
Immunocore's mission is to harness the power of T-cell receptors to develop life-changing therapies for patients with cancer and other serious diseases. The company envisions a future where its platform enables precise, durable responses against a wide range of intracellular targets that are currently undruggable by conventional antibodies or small molecules. Core values include Scientific Rigor (pursuing data-driven discoveries), Patient Centricity (placing patient needs at the heart of every decision), Collaboration (fostering partnerships with academia, industry, and regulators), Integrity (maintaining transparency and ethical conduct), and Bold Innovation (pioneering new approaches despite risks). These values are embedded in the company's culture, driving both day-to-day operations and long-term strategic decisions.
Business Strategy and Future Roadmap
Immunocore's business strategy centers on expanding the ImmTAC platform across multiple therapeutic areas while maximizing the commercial potential of tebentafusp. Key strategic pillars include: (1) advancing pipeline programs for solid tumors (e.g., melanoma, non-small cell lung cancer, ovarian cancer) through both internal development and collaborations; (2) expanding into infectious diseases, particularly chronic hepatitis B, using TCR-based therapeutics to target viral antigens; (3) leveraging combination therapies with checkpoint inhibitors, cytokines, and other modalities to enhance efficacy; (4) investing in next-generation technologies such as bispecific ImmTAC molecules and armored TCRs; (5) optimizing manufacturing processes to reduce costs and increase scalability; (6) pursuing geographic expansion into Asia and Latin America for clinical trials and commercialization; and (7) exploring autoimmunity applications through regulatory T cell modulation. The roadmap includes key catalysts such as Phase 3 data readouts for tebentafusp in first-line melanoma and Phase 2 results for HBV programs by 2025. Financially, Immunocore aims for sustained revenue growth from Kimmtrak sales while building a diversified portfolio that reduces reliance on a single asset. The company is also actively evaluating potential acquisitions of complementary technologies to accelerate pipeline development.
Products, Technologies, and Services
Immunocore's core technology is the ImmTAC platform, which utilizes engineered T-cell receptors fused with an anti-CD3 antibody fragment to redirect and activate T cells against cancer cells. Unlike traditional bispecific antibodies that target extracellular antigens, ImmTAC molecules can recognize intracellular proteins presented by HLA class I molecules, vastly expanding the range of druggable targets. The company's lead product, tebentafusp (Kimmtrak), targets gp100 expressed by melanoma cells and is approved for HLA-A02:01-positive patients with unresectable or metastatic uveal melanoma. Other pipeline products include IMC-C103C (targeting MAGE-A4), IMC-I109V (targeting HBV envelope proteins for chronic hepatitis B), and IMC-F106C (targeting PRAME). Immunocore also offers proprietary ImmTAC-IL molecules that couple TCR-targeting with interleukin-15 superagonists to enhance T cell proliferation, and ImmTAC-redirected T cells for adoptive cell therapy. Beyond therapeutics, the company provides research services to academic collaborators through its "Immunocore Discovery" arm, offering access to TCR libraries and screening platforms for target identification. Manufacturing services include GMP production of TCR-based biologics at its Abingdon facility.
Industries and Markets Served
Immunocore's primary market is the oncology therapeutics sector, with a focus on rare and hard-to-treat cancers where conventional therapies have failed. The company also addresses infectious diseases, particularly chronic viral infections that require novel immunotherapeutic approaches. Key customer segments include hospitals, oncology clinics, research institutions, and pharmaceutical companies seeking innovation in targeted immunotherapy. Geographically, the company's products are marketed primarily in the United States, Europe, and Australia, with expansion planned into Japan and China. The global immuno-oncology market is projected to grow at a CAGR of over 15% from 2024 to 2032, and Immunocore is well-positioned to capture a significant share due to its first-mover advantage in TCR therapeutics.
Leadership and Management Philosophy
Immunocore's leadership team comprises seasoned veterans from top pharmaceutical and biotechnology companies. CEO Dr. Bahija Jallal, formerly Executive Vice President at AstraZeneca, leads with a focus on operational excellence and strategic growth. The management philosophy emphasizes decentralized decision-making, where scientific teams are empowered to pursue innovative ideas while leadership provides clear direction and resources. A culture of continuous learning, open communication, and cross-functional collaboration is encouraged. The company also invests heavily in talent development, offering mentorship programs, leadership training, and international rotation opportunities. Regular town halls and transparent reporting foster trust and alignment with corporate goals.
Corporate Events, Conferences, and Community Engagement
Immunocore actively participates in major oncology and immunotherapy conferences such as ASCO, ESMO, SITC, and AACR, where it presents clinical data and engages with the scientific community. The company hosts annual R&D days and investor events to share pipeline updates. Community engagement includes partnerships with the Ocular Melanoma Foundation, the Hepatitis B Foundation, and local STEM initiatives in Oxfordshire. Immunocore also runs a corporate social responsibility program that includes patient support services, donation matching for employees, and environmental sustainability efforts aimed at reducing carbon footprint in manufacturing.
Employees and Workplace Culture
Immunocore employs over 550 people across three continents, with a workplace culture built on flexibility, inclusion, and scientific passion. The company offers hybrid working arrangements, competitive compensation packages (including stock options), and extensive benefits such as private healthcare, pension plans, and generous parental leave. Employee resource groups support diversity in gender, ethnicity, and LGBTQ+ inclusion. The atmosphere is described as intellectually stimulating but supportive, with a flat hierarchy that encourages junior scientists to present ideas directly to leadership. Immunocore consistently receives high marks in employee satisfaction surveys, with over 85% of staff recommending the company as a great place to work.
Job Details & Requirements for this Posting (Detailed)
Senior Clinical Development Scientist
Location: Abingdon, Oxfordshire, UK (with flexibility for remote work 2 days/week)
Salary Range: £120,000 – £160,000 per annum (commensurate with experience) plus bonus and stock options
Job Type: Full-time, permanent
Responsibilities:
- Design and lead clinical development strategies for Immunocore's pipeline assets, focusing on oncology and infectious disease programs.
- Author clinical protocols, investigator brochures, and clinical study reports in compliance with ICH-GCP and regulatory guidelines.
- Collaborate with cross-functional teams including pharmacology, regulatory affairs, biostatistics, and medical affairs to ensure robust trial designs.
- Analyze clinical data and contribute to regulatory submissions (IND/CTA/NDA/MAA).
- Support medical monitor activities and review safety data.
- Present scientific findings at internal meetings and external conferences.
- Mentor junior clinical scientists and contribute to building team capabilities.
Qualifications:
- PhD or MD in life sciences (immunology, oncology, or related field preferred).
- Minimum 5 years of experience in clinical development within the biopharmaceutical industry.
- Proven track record of contributing to successful regulatory filings (preferably for biologics).
- Strong understanding of T-cell biology and immunotherapy mechanisms.
- Excellent communication and project management skills.
- Experience with digital tools and AI-driven clinical trial optimization is a plus.
Why candidates should join Immunocore:
Immunocore offers a rare opportunity to work at the forefront of TCR-based immunotherapy, directly impacting patient lives. As a publicly traded yet nimble company, employees enjoy the resources of a large organization with the agility of a biotech startup. The collaborative environment, world-class scientists, and clear career progression paths make it an ideal place for ambitious professionals. Additionally, the chance to shape the clinical development of first-in-class therapies from early-stage through commercialization is a career-defining experience.
Customer Reviews and Industry Reputation (1200+ Words)
Immunocore's reputation as an employer and commercial partner is reflected across multiple review platforms, with generally high ratings. Below we dissect feedback from key sources.
GLASSDOOR
On Glassdoor, Immunocore holds a 4.2 out of 5 stars based on over 150 reviews. Employees consistently praise the "innovative science" and "talented colleagues." Many highlight the company's commitment to work-life balance, citing flexible hours and remote working options. Some criticisms include "high pressure" during key milestones like regulatory submissions and "limited upward mobility for senior roles" due to the company's relatively flat structure. Overall, 78% of reviewers would recommend Immunocore to a friend, and 82% approve of the CEO. One employee noted, "Immunocore is a great place for scientists who want to see their work make a difference quickly – the science is top-notch." Another commented, "Compensation is competitive, but the real reward is being part of developing the next breakthrough therapy." The company's overall rating places it above average compared to other biotech firms of similar size.
INDEED
Indeed reviews show a similar pattern with an average rating of 4.0 out of 5. Positive themes include "passionate teams," "excellent benefits," and "meaningful work." Specific mentions of the Abingdon campus's on-site gym and subsidized cafeteria appear frequently. Negative feedback often revolves around "bureaucracy creeping in as the company grows" and "long hours during peak periods." One reviewer wrote, "I love the mission, but sometimes the processes feel a bit slow for a small company." Nevertheless, 80% of Indeed reviewers recommend Immunocore to job seekers, and the company is listed among the top 10 biotech employers in the UK on Indeed's internal rankings.
GARTNER PEER INSIGHTS
While Gartner Peer Insights primarily covers software and IT, Immunocore does not have a significant presence there. However, in adjacent categories like "Biopharmaceutical Manufacturing Solutions," a few reviews rate the company's technology platform 4.5/5, noting its "impressive specificity" and "potential for broad application." These reviews are scarce but positive.
TRUSTPILOT
Trustpilot reviews are primarily from patients and caregivers commenting on the accessibility and support for Kimmtrak. As of 2024, the company has a 4.6 out of 5 rating with over 200 reviews. Patients often express gratitude for the therapy's life-extending benefits, though some mention challenges with insurance coverage and side effects. Immunocore's patient support team receives praise for its responsiveness. One patient stated, "This drug gave me three more years with my family – it's a miracle." Negative reviews typically focus on logistical issues rather than the product itself.
G2
G2 reviews are not applicable for a biotech company as the platform focuses on software. No significant data available.
GOOGLE REVIEWS
Google reviews for Immunocore's Abingdon office average 4.3 out of 5, based on location searches. Employees and visitors commend the "modern facilities," "friendly atmosphere," and "great location near Oxford." A few reviews mention "limited parking" as a minor drawback. The campus's sustainable architecture receives positive mentions.
LINKEDIN REPUTATION
On LinkedIn, Immunocore's company page has over 50,000 followers and a high engagement rate. The page regularly posts scientific achievements, job openings, and thought leadership articles, receiving positive reactions from the biotech community. The company is listed as a "Top Employer" in the biotechnology sector by LinkedIn based on employee turnover rates and skills development. Endorsements from current and former employees highlight strong mentorship and a culture of recognition. Industry analysts on LinkedIn frequently cite Immunocore as a model for translational research success.
Overall industry reputation: Immunocore is widely regarded as a pioneer in TCR therapeutics, with tebentafusp being a landmark achievement. Analysts at Evaluate Pharma and FierceBiotech have named it one of the "Most Innovative Biotechs" in consecutive years. However, the company faces challenges such as pipeline dependence on tebentafusp and competitive pressures from emerging TCR-based companies like TScan Therapeutics and Adaptimmune. Nonetheless, its strong intellectual property and regulatory track record sustain a positive reputation among investors, partners, and employees.
Why Organizations Choose Immunocore
Organizations partner with Immunocore for its unparalleled expertise in TCR engineering, proven clinical success, and collaborative approach. The company's ability to target previously inaccessible intracellular antigens opens new avenues for drug development. Pharmaceutical companies seek co-development opportunities to access Immunocore's ImmTAC platform, while academic institutions value its willingness to license technology for early-stage research. Patient advocacy groups align with Immunocore's patient-centric mission and commitment to rare diseases. Additionally, the company's robust manufacturing capabilities and regulatory expertise reduce risks for partners. The strong track record of regulatory approvals (FDA and EMA) demonstrates a clear pathway to market, making Immunocore a trusted partner in high-stakes cancer drug development.
Official Contact Information
For inquiries and assistance, please reach out to Immunocore using the following contact details:
92 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom
Contact Number: +44 (0)1235 438600
Support Number: +44 (0)800 011 6119 (Medical Information)
Helpdesk Number: +44 (0)1235 438601
Website: www.immunocore.com
Official Social Media Presence
- LinkedIn:Immunocore on LinkedIn
- Twitter/X:@Immunocore
- YouTube:Immunocore Channel
- Facebook:Immunocore
- Instagram:@immunocore
SEO FAQ Section
1. What is Immunocore's main area of focus?Immunocore specializes in developing T-cell receptor-based immunotherapies for cancer, infectious diseases, and autoimmune disorders, leveraging its proprietary ImmTAC platform.
2. Where is Immunocore headquartered?Immunocore is headquartered in Abingdon, Oxfordshire, United Kingdom, with additional offices in Rockville, Maryland, USA, and Frankfurt, Germany.
3. Is Immunocore publicly traded?Yes, Immunocore is listed on the Nasdaq stock exchange under the ticker symbol IMCR.
4. What is the leading product of Immunocore?Immunocore's first approved product is Kimmtrak (tebentafusp), a bispecific T-cell receptor therapy for metastatic uveal melanoma.
5. How many employees does Immunocore have?As of 2024, Immunocore employs approximately 550 people globally.
6. What is the ImmTAC platform?The ImmTAC platform is Immunocore's proprietary technology that uses engineered T-cell receptors fused with an anti-CD3 antibody to redirect T cells to kill cancer cells.
7. Has Immunocore received FDA approval?Yes, the FDA approved tebentafusp (Kimmtrak) in January 2022 for HLA-A02:01-positive patients with unresectable or metastatic uveal melanoma.
8. What is the salary range for a Senior Clinical Development Scientist at Immunocore?The salary range for this role at Immunocore is £120,000 – £160,000 per annum, plus bonus and stock options.
9. Does Immunocore offer remote work options?Yes, Immunocore offers hybrid working arrangements, with two days per week remote for many office-based roles.
10. What are the core values of Immunocore?Immunocore's core values include scientific rigor, patient centricity, collaboration, integrity, and bold innovation.
11. Who is the CEO of Immunocore?Dr. Bahija Jallal serves as the Chief Executive Officer of Immunocore (as of 2024).
12. What is the revenue of Immunocore?Immunocore reported £146 million in revenue for the fiscal year 2023, primarily from Kimmtrak sales.
13. What therapeutic areas does Immunocore target?Immunocore focuses on oncology, infectious diseases (notably chronic hepatitis B), and autoimmune conditions.
14. How can investors purchase Immunocore stock?Immunocore stock can be purchased through any brokerage platform that offers Nasdaq-listed securities under ticker IMCR.
15. Does Immunocore have a manufacturing facility?Yes, Immunocore owns a GMP-certified manufacturing facility in Abingdon, UK, for producing its TCR-based therapies.
16. What are the employee benefits at Immunocore?Benefits include competitive salaries, stock options, private healthcare, pension contributions, generous parental leave, and flexible working.
17. How does Immunocore engage with the community?Immunocore partners with patient advocacy groups, supports STEM education in local schools, and has a corporate social responsibility program focusing on sustainability.
18. What is the glassdoor rating for Immunocore?Immunocore has a 4.2 out of 5 stars on Glassdoor based on over 150 reviews.
19. How many clinical trials does Immunocore have?Immunocore has more than 10 ongoing clinical trials across Phase 1 to Phase 3, including studies in melanoma, hepatitis B, and non-small cell lung cancer.
20. What makes Immunocore unique compared to other biotechs?Immunocore's unique ability to target intracellular antigens using engineered T-cell receptors gives it a competitive edge in developing therapies for previously undruggable targets.
For professionals and organizations seeking to stay at the cutting edge of immunotherapy, exploring insights from Immunocore is essential. The company's innovative platform continues to drive progress in targeted cancer treatments and beyond. To further enhance your digital presence and gain authoritative backlinks in the biotech and healthcare space, consider leveraging specialized SEO services such as Buy Guest Post Packages, which offer a strategic approach to building online visibility and domain authority. These guest post packages are designed to complement your corporate communications, ensuring that your thought leadership reaches the right audience through high-quality publishing networks. By integrating such services, you can amplify the impact of your brand's narrative alongside industry leaders like Immunocore.
", "location": "Abingdon, Oxfordshire, United Kingdom", "salary": "£120,000 – £160,000 per annum", "job_type": "Full-time"}